The Use of Aeriseal ® in the Management of Collateral Ventilation Positive COPD Patients Undergoing ELVR Utilizing Endobronchial Valves.
Launched by MACQUARIE UNIVERSITY, AUSTRALIA · May 24, 2022
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • i. 18-85 years of age
- • ii. Forced Expiratory Volume in 1second (FEV1) 20 - 50%
- • iii. Residual Volume (RV) \> 175%
- • iv. 6 min walk test \> 150 m
- • v. Completed a course of Pulmonary rehabilitation
- • vi. STRATX assessment - Left Upper Lobe as the most appropriate lobe to target for ELVR
- • vii. This study will be investigating heterogenous emphysema only. Minimum of 15% differential in emphysema destruction scores at -950 HU
- Exclusion Criteria:
- • i. Acute uncontrolled medical illness including ischemic heart disease, cardiac failure, acute renal impairment
- • ii. Acute respiratory tract infections
- • iii. Significant bronchiectasis,
- • iv. Co-existing interstitial lung diseases, pneumothorax,
- • v. Known active malignancy
- • vi. Pregnancy.
About Macquarie University, Australia
Macquarie University, located in Sydney, Australia, is a leading institution renowned for its commitment to innovative research and education across various disciplines, including health sciences. The university actively sponsors clinical trials aimed at advancing medical knowledge and improving patient outcomes. With a focus on interdisciplinary collaboration, Macquarie University leverages its state-of-the-art facilities and expert faculty to conduct rigorous research that adheres to ethical standards and regulatory guidelines. Its clinical trials encompass a broad spectrum of therapeutic areas, reflecting the university's dedication to addressing pressing health challenges and contributing to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Macquarie Park, New South Wales, Australia
Patients applied
Trial Officials
Alvin J Ing, MBBS, MD, FRACP
Principal Investigator
Clinical Professor and Respiratory Physician
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials